Your session is about to expire
← Back to Search
RGX-202 Gene Therapy for Duchenne Muscular Dystrophy
Study Summary
This trial tests a new gene therapy to help treat Duchenne muscular dystrophy, testing safety, tolerance and effectiveness of a one-time IV dose.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have been on a stable dose of steroids for at least 12 weeks before my recent tests.I can walk 100 meters on my own without help.I do not have any conditions that prevent me from taking immunosuppressive drugs.I have taken ataluren or exon-skipping therapy for DMD within the last 6 months or cannot stop taking it for 5 years after starting RGX-202.My liver and kidney tests are normal or not concerning.My heart's pumping ability is below normal.My DMD is caused by a mutation in exon 18 or higher.I can complete the required standing test as per the study's guidelines.
- Group 1: RGX-202 Dose 1
- Group 2: RGX-202 Dose 2
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the capacity of the study in terms of participants?
"Correct. Clinicaltrials.gov data suggests that this medical trial, posted on January 1st 2023, is actively recruiting patients for inclusion. 18 participants need to be found from one particular site."
Is this medical experiment open to elderly individuals aged 75 and up?
"This clinical trial is intended for children with ages ranging from 4 to 11. Additionally, there are 61 studies available to minors and 52 research opportunities open to senior citizens."
Are there vacancies available for potential participants of this trial?
"Affirmative. Data hosted on clinicaltrials.gov confirms that this medical research, which was originally uploaded on the first day of January in 2023, is actively recruiting volunteers. Approximately 18 participants need to be recruited from 1 distinct site."
Do I meet the requirements to partake in this scientific investigation?
"This medical trial seeks to recruit 18 children between the ages of 4 and 11 who suffer from Duchenne muscular dystrophy. To be eligible, patients must possess a DMD gene mutation in exons 18 or above; they also need to be able to complete certain physical tasks without any assistive devices, have been taking standard glucocorticoid doses for at least 12 weeks prior to screening, and display normal laboratory tests results."
Share this study with friends
Copy Link
Messenger